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Conclusion: In conclusion, we improved and validated a 
clinical model with inclusion of hypoxia and tumor-load 
related blood-biomarkers. New immunological markers were 
associated with overall survival. Currently we are aiming to 
extend these models to include imaging information 
(Radiomics). 
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Purpose or Objective: Intensity-modulated radiation therapy 
(IMRT) and volumetric-modulated arc therapy (VMAT) are 
widely used in the treatment of advanced stage non-small 
cell lung cancer (NSCLC). These techniques deliver conformal 
dose distributions at the cost of increased target dose 
heterogeneity (particularly IMRT) and larger volumes of 
surrounding healthy tissues receiving low doses (particularly 
VMAT). We evaluated whether these dosimetric differences 
between IMRT and VMAT are of influence on treatment 
toxicity and outcome. 
 
Material and Methods: We retrospectively assessed a cohort 
of 189 consecutive patients with stage III NSCLC having 
undergone radical (chemo-)radiotherapy using IMRT (until 
2011) or VMAT (starting in 2011 ). Most patients (n=182) 
received 66 Gy in 33 (once-daily) fractions to the primary 
tumour and involved hilar/mediastinal lymph nodes based on 
FDG-PET/CT. Concurrent chemoradiation (CCR; n=122) 
consisted of 2 courses of etoposide cisplatinum, whereas 
sequential treatment (n=56) consisted of 3 courses of 
gemcitabine cisplatinum. Acute and late toxicity were 
assessed using the RTOG radiation morbidity scoring criteria 
for esophageal and pulmonary toxicity. Follow-up visits were 
planned every 3 months (first 2 years), biannually thereafter. 
Median overall survival (OS) was calculated using Kaplan-
Meyer survival analysis. Differences between the groups 
receiving IMRT and VMAT were statistically tested using the 
Mann-Whitney-U or Chi-square test, where appropriate. 
 
Results: Gender, age, performance score, clinical (tumour 
and nodal) stage and radiation dose did not significantly 
differ between the IMRT (n=93) and VMAT (n=96) groups. 
Patients undergoing IMRT, however, received less concurrent 
chemotherapy compared to patients treated with VMAT (n=51 
vs n=71; p= 0.007). Incidences of grade ≥2 and ≥3 acute 
esophageal toxicity (AET) were significantly lower for IMRT 
compared to VMAT (28 vs 57 patients, p<0.001; and 6 vs 17 
patients, p=0.025, respectively). Maximum grade acute and 
late pulmonary toxicity did not differ between groups (p=0.57 
and p=0.14, respectively). Grade ≥3 late esophageal toxicity 
was scored in 1 and 3 patients after IMRT and VMAT, 
respectively. Median follow-up for the patients alive was 32 
months (range 2.4-82.1 months). Median OS was 23.9 months 
(95% CI 19.6-28.1), without a significant difference between 
the groups (23.9 and 24.9 months for IMRT and VMAT, 
respectively; p=0.70). 
 
Conclusion: Patients treated with VMAT showed significantly 
higher incidence of Grade ≥2 and ≥3 AET, which may be due 
to a higher percentage of patients receiving CCR in the 
VMAT-group. Median OS did not differ between groups. 
Currently the target volumes and dosimetric data are 
evaluated for differences between the groups, for we 
hypothesized that VMAT enables treatment of larger tumour 
volumes, leading to increased AET. 
 
PO-0680  
Predictive models of the extent and CT appearance of 
radiation induced lung injury for NSCLC 
U. Bernchou
1Odense University Hospital, Laboratory of Radiation Physcis, 
Odense, Denmark 
1, R. Christiansen1, J. Asmussen2, T. Schytte3, O. 
Hansen3, C. Brink1 
2Odense University Hospital, Department of Radiology, 
Odense, Denmark 
3Odense University Hospital, Department of Oncology, 
Odense, Denmark 
 
Purpose or Objective: The purpose of the present study was 
to investigate the extent and appearance of early radiologic 
injury in the lung after radiotherapy (RT) for non-small cell 
lung cancer (NSCLC). Furthermore, the ability of planned 
mean lung dose to predict the risk of a radiologic response 
was explored. 
 
Material and Methods: Eligible follow-up computed 
tomography (CT) scans acquired within 6 months after 
commencement of radiotherapy were retrospectively 
evaluated for radiologic injuries in a cohort of 213 NSCLC 
patients treated to 60 or 66 Gy in 2 Gy fractions at a single 
institution from 2007 to 2013. Radiologic injuries were 
divided in two categories based on CT appearance. Category 
1 represented ground-glass opacity (GGO) and interstitial 
changes. Both are characterized by moderately increased 
densities in the lung parenchyma, but where GGO appears 
diffuse, amorphous, and with poorly defined vessel 
structures, interstitial changes are identified by more 
pronounced vessels and borders. Category 2 indicated patchy 
or confluent consolidation in the lung. The volume fraction of 
injured lung corresponding to either category was estimated 
in each scan. To investigate the relationship between the 
volume fraction of injured lung and mean lung dose, a 
logistic regression analysis was performed. Four different cut-
points were chosen to define radiologic injury response. 
These were volume fractions of injured lung larger than 5%, 
10%, 15%, or 20%. Both individual and combined categories 
were investigated. 
 
Results: Radiologic injuries of category 1 and 2 were found in 
follow-up scans for 81% and 42% of the patients, respectively. 
The mean volume fraction of injured lung was 6.5% (range 0-
95%) and 1.7% (range 0-22%) for category 1 and 2, 
respectively, and 8.2% (range 0-95%) when the categories 
were combined. The logistic normal tissue complication 
probability (NTCP) models are shown in the figure for the 
combined categories of lung appearance. The risk of 
radiologic response was found to be significantly associated 
with mean lung dose. The mean lung dose resulting in 50% 
risk of radiologic response (D50) increased from 17 to 29 Gy 
as the cut-point used for dichotomization increased from 5 to 
20% of volume fraction of affected lung (see table). A logistic 
relationship between radiologic response and mean lung dose 
was also found for the individual categories of lung 
